TY - JOUR
T1 - Anagrelide as a new platelet-lowering agent in essential thrombocythemia
T2 - Mechanism of action, efficacy, toxicity, current indications
AU - Tefferi, Ayalew
AU - Silverstein, Murray N.
AU - Petitt, Robert M.
AU - Mesa, Ruben A.
AU - Solberg, Lawrence A.
PY - 1997/1/1
Y1 - 1997/1/1
N2 - Anagrelide is an oral imidazoquinazoline agent with an anti-cyclic AMP phosphodiesterase activity and inhibits platelet aggregation in both humans and animals. In addition, it has in humans a species-specific platelet- lowering activity observed at dose levels lower than those required to inhibit platelet aggregation. Because of this, the drug has been tested in patients with clonal thombocytasis and has been shown to have potent platelet-reducing activity in essential thrombocythemia (ET) and related disorders. The mechanism of action may involve the drug's interference with megakaryocyte maturation. More than 90% of patients with ET respond to anagrelide regardless of the presence or absence of previous therapy. The responses are durable with a median maintenance dose of approximately 2 to 2.5 mg/day. Side effects are related mostly to the drug's direct vasodilating and positive inotropic effects and include headache, fluid retention, tachycardia, and arryhthmias. The place of anagrelide therapy in the current management of patients with ET is discussed.
AB - Anagrelide is an oral imidazoquinazoline agent with an anti-cyclic AMP phosphodiesterase activity and inhibits platelet aggregation in both humans and animals. In addition, it has in humans a species-specific platelet- lowering activity observed at dose levels lower than those required to inhibit platelet aggregation. Because of this, the drug has been tested in patients with clonal thombocytasis and has been shown to have potent platelet-reducing activity in essential thrombocythemia (ET) and related disorders. The mechanism of action may involve the drug's interference with megakaryocyte maturation. More than 90% of patients with ET respond to anagrelide regardless of the presence or absence of previous therapy. The responses are durable with a median maintenance dose of approximately 2 to 2.5 mg/day. Side effects are related mostly to the drug's direct vasodilating and positive inotropic effects and include headache, fluid retention, tachycardia, and arryhthmias. The place of anagrelide therapy in the current management of patients with ET is discussed.
KW - Anagrelide
KW - Essential thrombocythemia
KW - Mechanism of action
KW - Side effects
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0030803837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030803837&partnerID=8YFLogxK
U2 - 10.1055/s-2007-996112
DO - 10.1055/s-2007-996112
M3 - Review article
C2 - 9263355
AN - SCOPUS:0030803837
VL - 23
SP - 379
EP - 383
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
SN - 0094-6176
IS - 4
ER -